WCN26-6189 Long-Term Cost Reduction and Dose Optimization of Roxadustat in Hemodialysis Patients: A 100-Week Longitudinal Analysis

Read full text Summarise with VIRAT
Authors: Kenji Sawase, Jyunichiro Hashiguchi, Akihiro Maekawa, Koutaro Shimoyama
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Roxadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, was first introduced in Japan in 2019 and subsequently adopted in several countries for anemia management in chronic kidney disease (CKD) and hemodialysis (HD) patients. Although initially more expensive than erythropoiesis-stimulating agents (ESAs), HIF-PH inhibitors represent a novel therapeutic class with broader metabolic effects through activation of multiple hypoxia-responsive genes. This study investigated the long-term cost trajectory and dose trends of roxadustat compared with conventional EPO therapy in HD patients.

Fields of Study & Subjects

Erythropoietin and Anemia Treatment Dialysis and Renal Disease Management Health Systems Economic Evaluations Quality of Life

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104846–104846
Publication date
25 March 2026
Language
EN